QUOTE AND NEWS
FierceBiotech  Aug 27  Comment 
Ted Tenthoff, an analyst for Piper Jaffray, was clearly pumped about the prospects of an Achillion buyout when a reporter from Bloomberg reached him.
StreetInsider.com  Aug 26  Comment 
52-Week High: Achillion Pharma (Nasdaq: ACHN) $11.96. Achillion Pharma making some serious gains Tuesday as M&A speculation runs rampant in the sector. Chatter heated up following Roche's move to acquire Intermune, which was announced last...
Benzinga  Aug 26  Comment 
Achillion Pharmaceuticals (NASDAQ: ACHN) and Arrowhead Research (NASDAQ: ARWR) were up sharply Tuesday after an analyst said the pair of drug development companies could become takeover targets. "If you want to compete with Gilead, you have to...
TheStreet.com  Aug 26  Comment 
NEW YORK (TheStreet) --aAchillion Pharmaceuticalsa touched another 52-week high of $12 on Tuesday after UBS tabbed the company as a possible takeover target on Monday in the wake ofaRoche'sa$8.3 billion bid foraInterMune . The deal led the...
Benzinga  Aug 26  Comment 
Kite Pharma (NASDAQ: KITE) jumped 19.06% to $26.55 in pre-market trading on positive non-Hodgkin's lymphoma trial results using KTE-C19. Kandi Technolgies Group (NASDAQ: KNDI) shares gained 8.37% to $19.80 in pre-market trading on report that...
Benzinga  Aug 25  Comment 
Shares of Achillion Pharma (NASDAQ: ACHN) got a mid-day pop Monday following some bullish comments from UBS's Andrew Peters. The stock rallied more than six percent following the release of the intraday research note, adding onto an already 4.7...
TheStreet.com  Aug 25  Comment 
NEW YORK (TheStreet) --aAchillion Pharmaceuticalsa asurged to a 52-week high of $11.15 in afternoon trading Monday afteraUBSatabbed the company as a possible takeover target. Roche'sa$8.3 billion bid foraInterMunea led the biotech sector up on...
TheStreet.com  Aug 19  Comment 
NEW YORK (TheStreet) --aAchillion PharmaceuticalsaACHN rose in after-hours trading Tuesday after the company received a patent for its hepatitis C drug ACH-3102. The U.S.aPatent & Trademark Office granted U.S. Patent No. 8,809,313 to the company....
Benzinga  Aug 19  Comment 
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally...
StreetInsider.com  Aug 18  Comment 
UPGRADES Deutsche Bank upgrades Achillion Pharmaceuticals (Nasdaq: ACHN) from Hold to Buy and moves its price target from $6 to $17. Click Here for more color. Monness, Crespi, Hardt moves Hewlett-Packard (NYSE: HPQ) from Neutral to...





You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki